In the phase 2 TheraP study (n = 200) the investigators utilized prespecified cutoff points for SUVmean, observing that whole-body tumor SUVmean values of ≥ 10 were significantly associated with a favorable PSA response to [177Lu]Lu-PSMA-617 treatment compared with cabazitaxel (OR, 12.19; 95% CI, 3.42–58.76 vs 2.22; 95% CI, 1.11–4.51; padj = 0.039 for treatment-by-SUVmean interaction) (40). Here, FOLH1 is linked to neoplasm.